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Abstract
Background: Uterine fibroids are the most common benign tumor of the reproductive tract in women. Uterine
artery embolization has been approved as an alternative treatment option for uterine fibroids to reduce uterine and
fibroid volumes as well as to relieve the patient symptoms. The current study included 80 patients with
symptomatic uterine fibroids. All patients underwent pre-embolization MRI, uterine artery embolization, and follow-
up post-embolization MRI at 6 months post procedure for a reduction in uterine and dominant fibroid volumes.
The aim of the study was to assess the role of transcatheter uterine artery embolization in reducing the uterine
fibroid volume.
Results: There was a significant difference in the uterine volume reduction between a group with single fibroids
and a group with multiple uterine fibroids The mean uterine volume reduction in the first group was 46.5%
compared to 37.4% reduction in the second group. While there was no significant difference in the dominant
fibroid volume reduction between both groups (48.8% and 44.9% respectively).
Conclusions: UAE has a high efficacy in the reduction of both the uterine volume and the dominant fibroid
volume, which results in improvement in patient’s quality of life.
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Background
Uterine fibroids (UF) are the commonest benign tumor
in women of reproductive age [1]. Fibroids may vary in
size from a few millimeters to large sizes (over 10 cm)
and can be classified into single or multiple uterine
fibroids [2].
Uterine artery embolization (UAE) is an interventional
radiological (IR) technique to occlude the arterial supply
to the uterus for various reasons [3].
The technique was first reported as an effective tech-
nique for the treatment of uterine fibroids in 1995, when
it was noted that women with symptomatic fibroids who
underwent UAE as a pre-hysterectomy treatment had
significant clinical improvement to the extent that
hysterectomy was no longer required [4].
UAE has proved to be an effective treatment for symp-
tomatic fibroids and it is now considered as an alterna-
tive to myomectomy and hysterectomy [5, 6]. Standard
imaging protocols for UAE are the pre-procedural as-
sessment by magnetic resonance imaging (MRI) followed
by a post-procedural MRI 3–6 months later [7, 8].
Embolization procedures are performed with 4F RIM
catheter, microcatheters, and a variety of embolic agents.
One of the decisions that an operator must make before
performing a uterine artery embolization procedure is
which embolic agent to use. Originally, irregularly
shaped polyvinyl alcohol (PVA) particles were used,
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although more recently other spherical-shaped embolic
agents have been developed [9, 10].
Infarction of a fibroid is indicated by the absence of
contrast enhancement in follow-up T1-weighted MR im-
ages in comparison to pre-embolization MRI images.
The degree of infarction is expressed by using a scale
from 0 to 100% infarction, where 100% is complete in-
farction and 0% is non-infarction [11].
Persistent symptoms after UFE can be due to incom-
plete fibroid infarction, and the subsequent regrowth of
an incompletely treated fibroid contributes to earlier
symptom recurrence [12].
Methods
Eighty female patients were referred for UAE for symp-
tomatic fibroids. UAE for fibroids was decided after dis-
cussion of treatment options in a fibroid multidisciplinary
team meeting. Exclusion criteria were a positive pregnancy
test, uterine or adnexal infection, suspected gynecologic
malignancy, patients with renal impairment, and hyper-
sensitivity to contrast media.
Patients were examined in both gynecology and IR
clinics with a full detailed history, including the men-
strual history, duration and amount of bleeding, and full
laboratory investigations. Informed consent was obtained
from all patients and patient information leaflets were
given to them during the clinic visit.
Pre and post procedure pelvic MRI
Pelvic MRI was performed using a GE Signa Excite (GE
Medical Systems, USA) 1.5 Tesla MRI scanner. Pre- and
post-interventional MRIs were performed according to
standard identical protocols.
The MRI sequences used in the study were sagittal T2
fast spin echo (FSE), axial T2 FSE, axial T1 FSE, and
post contrast axial T1 fat-saturated imaging. Assessment
criteria were the site and number of fibroids, the calcula-
tion of pre and post embolization uterine and dominant
fibroid volumes, and the estimation of the percentage of
dominant fibroid infarction on the post embolization
MRI scans.
Clinical symptomatic improvement was assessed with
by calculation of symptom severity score and a health-
related quality of life questionnaire (HR-QOL) before
and 6months after UAE.
Technique of uterine artery embolization
The procedure was done under fluoroscopic guidance
using a Siemens Artis-Q Angiography machine with a
ceiling mounted system. The machine is capable of serial
radiography and digital subtraction. Non-ionic contrast
media (Omnipaque 300) was used in all patients (Figs. 1
and 2).
The embolization procedure was performed by certi-
fied interventional radiologists in our institution (R.M.
with 30 years experience in interventional radiology,
A.K. 15 years experience, and A.E. 10 years experience).
Each operation was performed by two operators to de-
crease operative time and radiation exposure.
The patient is positioned in the supine position, and
both groins are prepped with antiseptic solution. Bilat-
eral common femoral arteries access is achieved using
the Seldinger technique after infiltration of local
anesthesthetic agent (10 ml lidocaine) around the fem-
oral artery.
Then 4F Rim catheters (Rosch Inferior Mesenteric
Torcon Beacon Tip catheter, Cook Medical, USA) are
advanced over the aortic bifurcation over 0.035 hydro-
philic guidewires (Radiofocus® Terumo) to reach the
contra-lateral internal iliac artery. Catheterization of the
uterine artery is then performed, and the catheter tip is
placed in the transverse portion of the uterine artery.
Arteriography is performed to confirm a satisfactory
position.
In some patients, it was difficult to access the correct
position with the Rim catheter. In these cases, a 2.7F
microcatheter (Progreat 2.7F microcatheter, Terumo
Medical Corporation, Europe) was used to go further to
access the appropriate position. Pulsed fluoroscopy (2
pulses per second) is used to opacify the entire fibroid
uterus and to decrease patient radiation dose.
Embolization is started using 355 to500 μm non-
spherical polyvinyl alcohol particles (Contour PVA,
Boston Scientific, USA), which are then upsized to 500 to
710 μm and 710–1000 μm.
The end point for embolization is stasis of contrast
within the transverse segments of the uterine arteries for
approximately 10 cardiac pulsations.
The operators usually wait for a period of 5 min to
allow any remaining embolic material clumping to redis-
tribute, and they then reconfirm adequate stasis by
performing repeat angiography.
Following UAE, patient-controlled analgesia with the
administration of intravenous analgesia and anti-
inflammatory drugs may be used to assist in pain control
in the early post procedure period.
After UAE, patients are observed overnight in the hos-
pital to ensure adequate access to pain and anti-nausea
medications and to enable observation of the femoral
access site.
Merits and limitation of technique
The merits of the uterine fibroid embolization are as fol-
lows: avoidance of hysterectomy, minimally invasive
technique, shorter hospital stay, and shorter recovery
time. However, this technique cannot be used in patients
with uterine or adnexal infections, renal impairment,
Elsharkawy et al. Egyptian Journal of Radiology and Nuclear Medicine           (2020) 51:77 Page 2 of 7
Fig. 1 Forty year-old-female patient. a Sagittal T2-weighted MR image shows a single large intramural fibroid. b A baseline MRI scan shows
intense enhancement of the fibroid. c Uterine arteriograms before embolization: Fluoroscopic image obtained in the arterial phase shows
bilateral hypertrophied uterine arteries with a large fibroid uterus due to uterine fibroids. d Sagittal T2-weighted MRI 6 months following uterine
artery embolization demonstrates a reduction in the uterine and fibroid volume. e Post embolization T1-weighted MR image shows 100%
infarction with decreased fibroid volume
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Fig. 2 (See legend on next page.)
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and patients with known history of hypersensitivity to
contrast media.
Statistical analysis
The collected data were coded, tabulated, and statisti-
cally analyzed using the SPSS program (Statistical Package
for Social Sciences) software version 25.
Descriptive statistics were done for parametric quanti-
tative data by mean, minimum, and maximum of the
range, while they were done for categorical data by num-
ber and percentage.
Analyses were done for parametric quantitative data
using paired samples T test.
The level of significance was taken at a P value of
< 0.05.
Results
Eighty patients with uterine leiomyomata were referred
to the IR department between February 2018 and Octo-
ber 2019. They were recruited into the study after fulfill-
ment of the inclusion criteria; their ages ranged from 34
to 54 years old; the patients were classified into 2 groups:
21 patients in the first group (group 1) had a solitary
large fibroid, and 59 patients in the second group (group
2) had multiple fibroids. Patients complained of uterine
bleeding and/or pelvic pressure symptoms in the form of
pelvic heaviness and urinary disturbance (as in Table 1).
There was a significant difference in the percentage of
uterine volume reduction between the two groups. In
group 1, the pre-embolization uterine volume was 179–
3628 cm3 with a mean volume = 608.1 cm3 and total vol-
ume reduction was 46.5%. The pre-embolization total
uterine volume in group 2 was 84.3–2179 cm3 with a
mean volume = 872.9 cm3 and total volume reduction
was 37.4% (significant difference, P = 0.01) (as shown in
Table 2).
However, there was no significant difference of the vol-
ume reduction of the dominant fibroid between the 2
groups. The pre-embolization dominant fibroid volume in
group 1 group ranged from 52–290 cm3 (mean = 270
cm3), and the volume reduction was 48.8%. In group 2,
the pre-embolization volume ranged from 23–170 cm3
(mean = 247 cm3) and the volume reduction was 44.9%
(no significant difference, P = 0.57) (as shown in Table 3).
 The number of PVA vials that were used in group 1
ranged from 2–10 vials with a mean of 4.7 vials,
while in group 2, the number of PVA vials that were
used ranged from 2–12 vials with a mean of 5 vials.
 As regarding procedural complications, expulsion of
the infarcted fibroid occurred in 2 patients who
presented with severe colicky pain. No major
complication or puncture site hematoma was
encountered.
 The mean screening time was 15.68 min; the mean
radiation dose was 191 mGy; and there was no
significant difference in the dose area product (DAP)
of 2520 μGym2, fluoroscopy time, or radiation dose
between the two groups.
 In group 2, failure to cannulate the left uterine
artery by the RIM catheter was experienced in 5
patients and the right uterine artery in one patient
with the result that microcatheters were used in
these patients. In group 1, there was failure to
catheterize the left uterine artery with the RIM
catheter in one patient, and a microcatheter was
used successfully.
 In group 1, the mean symptom severity score was
65.8 before UAE and was 30.4 after UAE. The mean
HR-QOL before UAE was 33.3, was 78.2 after UAE,
which was not statistically significant different (P
value = 0.67) from group 2. In group 2, the mean
pre-UAE symptom severity score was 70.1 and was
(See figure on previous page.)
Fig. 2 Thirty-five year-old-female patient. a Sagittal T2-weighted MR image demonstrates multiple variably sized uterine fibroids. b Baseline T1-
weighted fat-suppressed image shows an intense enhancement of the uterine fibroids. c Uterine angiograms before embolization: fluoroscopic
image obtained in the arterial phase shows bilateral enlarged uterine arteries with an enlarged uterus due to multiple fibroids. d Post
embolization T1-weighted fat-suppressed image shows 100% infarction of the dominant fibroid and decreased uterine and fibroid volumes. e
MRI scan 6 months post UAE shows a reduction in the uterine and fibroid volumes
Table 1 Number, age, and complaints of the two studied
groups
Treatment group
Single fibroid Multiple fibroids
Number of patients 21 59
Age (mean) 42.7 43.3
Menorrhagia 16 39
Pelvic pressure 10 22
Table 2 Total uterine volume reduction percentage
Uterine volume reduction Treatment group
Single fibroid Multiple fibroids
Pre embolization mean volume 608.1 cm3 872.9 cm3
Post embolization mean volume 325 cm3 550 cm3
Volume reduction 46.5% 37.4%
P value 0.01*
(*) means statistically significant
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32.8 after UAE, and the HRQOL was 40.2 and 74,
respectively (Table 4).
At 6months follow-up at the MRI unit, complete in-
farction of the dominant leiomyoma was achieved in 18
patients (85.7 %) in group 1, which had a statistically
significant difference (P value 0.03*) compared with the
group 2 in which complete infarction was achieved in 34
patients (57.6%), as listed in Table 5.
Complications in group 2 included severe pain in two
patients after discharge from hospital within 1 week that
required readmission and IV analgesia, complete expul-
sion of a dominant fibroid in one patient, and infection
in two patients, which was treated by IV antibiotics and
hospital readmission.
Spasm of right uterine artery was experienced in one
patient with a failed embolization from that side and
successful embolization of the left uterine artery. At
follow-up, successful fibroid infarction was achieved.
Complications in group 1 were expulsion of the fibroid
in one patient, severe pain in one patient requiring
readmission, and pain control.
Discussion
UAE has become a popular treatment option for women
with symptomatic fibroids who desire uterine preserva-
tion and/or the avoidance of surgical intervention [7].
Our results have demonstrated that there was a signifi-
cant reduction in the uterine volume between the stud-
ied groups with total volume reduction in 46.5% and
37.4 % in group 1 and group 2, respectively (P = 0.01).
However, there was no significant difference in the
reduction of the dominant fibroid volume between the
two groups with volume reduction of 48.8% and 44.9%
in group 1 and group 2, respectively (no significant
difference, P = 0.57).
Das et al.’s [9] study revealed that the dominant fibroid
volume mean reduction was 50% at 6 months, while the
mean uterine volume reduction was 42% at 4 months.
 At 6 months MRI follow-up, complete infarction of
the dominant leiomyoma was achieved in 18 pa-
tients (85.7 %) in group 1, and complete infarction
was achieved in 34 patients in group 2 (57.6%). In
the study of Richard et al. [13], complete dominant
tumor infarction was maintained at 3 months in
82.1% of patients in the PVA UAE group.
 With the use of PVA as our main embolic agent, we
achieved satisfactory clinical success. In group 1, the
mean symptom severity score markedly decreased
from 65.8 to 30.4 after treatment, and the mean
HRQOL improved from 33.3 to 78.2. While in
group 2, the mean symptom severity score was 70.1
pre-procedure and 32.8 post procedure, and the
HRQOL improved from 40.2 to 74.
In a study by Das et al. in 2014 [9], HR-QOL improved
from 39.1 pre UAE to 76.2 post UAE, and symptom se-
verity score decreased from 55.9 to 26.6 before and after
UAE, respectively.
All patients with uterine fibroids were treated by UAE
using bilateral arterial femoral artery access. The mean
screening time was 15.68 min, the mean dose was 191
mGy, and the dose area product (DAP) was =
2520 μGym2 with no significant differences detected with
Table 3 Dominant fibroid volume reduction percentage
Fibroid volume reduction Treatment group
Single fibroid Multiple fibroids
Pre embolization mean volume 270 cm3 247 cm3
Post embolization mean volume 138 cm3 136 cm3
Volume reduction 48.8% 44.9%
P value 0.57
Table 4 Mean symptom severity score and mean HR QOL
Single fibroid group Multiple fibroids group
Mean symptoms severity score Mean HR-QOL Mean symptoms severity score Mean HR-QOL
Pre UAE 65.8 33.3 70.1 40.2
Post UAE 30.4 78.2 32.8 74
Mean difference between Pre/Post 35.4 44.9 37.3 33.8
P value 0.67
Table 5 Dominant Fibroid infarction
Dominant Fibroid infarction
Single fibroid group Multiple fibroids group
(n) (%) (n) (%)
100% 18 85.7 34 57.6
99–90% 2 9.5 16 27.1
75–90% 1 4.7 3 5
50–74% 0 0 2 3.3
< 50% 0 0 4 6.6
P value 0.03*
(*) means statistically significant
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respect to fluoroscopy time or radiation dose between the
two groups.
In a study by Bratby et al. [14], elective bilateral arter-
ial punctures were reported aiming to reduce patient
irradiation by using pulsed fluoroscopy, avoidance of
aortography, and simultaneous bilateral embolization.
The study results are limited by unequal number of
patients in the study groups, so further study from
multiple centers is recommended for better assessment.
Conclusion
UAE has high efficacy in reducing uterine volumes in
the patients with a single fibroid. The results of UAE are
improved in patients with single fibroids rather than
multiple fibroids. UAE improved the quality of life
whether patients had single or multiple fibroids.
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